학술논문

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Document Type

Article

Author

Weisel, K.; Krishnan, A.; Schecter, J.M.; Jackson, C.C.; Yeh, T.-M.; Vogel, M.; Valluri, S.; Deraedt, W.; Banerjee, A.; Yalniz, F.; Nesheiwat, T.; Van Sanden, S.; Diels, J.; Usmani, S.Z.; Berdeja, J.G.; Jagannath, S.; Martin, T.

Source

In: Clinical Lymphoma, Myeloma and Leukemia. (Clinical Lymphoma, Myeloma and Leukemia, September 2022, 22(9):690-701)

Subject

Language

English

ISSN

21522669
21522650

Online Access

Full Text (ScienceDirect 종량제) Full Text (Clinical Key) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송